Sign in
WithdrawnPhase 2/3

Terbutaline Sulfate in Adults With Asthma

Key facts

Who runs it
Kanecia Obie Zimmerman
Where
Aurora and Burlington, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Phase
Phase 2/3
Started
7 Jul 2023
Expected to end
Dec 2026
Type of study
Interventional, 5 groups
Treatments tested
  • Terbutaline
Record updated
22 January 2026
Why it stopped
The TBS02 study was paused indefinitely. No subjects were enrolled or treated, and the study may resume if circumstances change.

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Participant has provided informed consent
  • History of physician-diagnosed asthma
  • Age ≥18 to <60 at time of consent
  • Past (within 12 months of consent) or current (at screening visit)evidence of airway reactivity, defined as:; Documentation of ≥10% FEV1 improvement following bronchodilator OR; Positive methacholine challenge (20% or more FEV1 decrease at ≤ 16 mg/mL)
  • Willing and able to undergo study procedures and attend required study visits
  • Adequate venous access for blood draws and drug administration, as determined by study investigator, or designee
  • Weight ≥ 40kg
  • FEV1 ≥ 60% predicted on day of terbutaline sulfate dosing
  • Systolic blood pressure (BP) ≤ 150 millimeters of Mercury (mmHg) and diastolic BP ≤ 90 mmHg measured after 10 to 15 minutes of rest
  • Heart rate > 45 and < 110 beats per minute (bpm) measured after 10 to 15 minutes of rest
  • Female participants of child-bearing potential: negative pregnancy test (urine hCG) and agreement to use effective contraception (complete abstinence from vaginal intercourse, combination barrier and spermicide, partner vasectomy, bilateral tubal ligation, intrauterine device (IUD), progestin implants, or hormonal) during study participation

Who cannot take part

  • Previous enrollment in the current study (any part)
  • History of ocular, brain, abdominal or thoracic surgery in the 12 months prior to screening
  • Self-reported respiratory tract infection in the 14 days prior to Visit 1
  • Participation in another research study that includes use of any investigational drug treatment within the 30 days prior to Visit 1, or planned participation during the study period
  • Any chronic respiratory condition besides asthma (including, but not limited to Chronic Obstructive Pulmonary Disease (COPD), emphysema, or interstitial lung disease) that in the opinion of the Principal Investigator (PI) or clinical site investigator, would make the participant unsuitable for the study
  • Known hypersensitivity to terbutaline sulfate or albuterol
  • Any current chronic condition or past history of disease that, in the opinion of the PI would make the participant unsuitable for the study
  • Moderate to severe renal impairment, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2
  • Any history of cardiac disease (e.g. coronary insufficiency, cardiac arrhythmias), non-skin cancer, hyperthyroidism, diabetes mellitus type 1, uncontrolled diabetes mellitus type II (HbA1C>7.5 documented within past 12 months of screening) uncontrolled epilepsy (2 or more seizures within the past 12 months and not taking anti-seizure medication)
  • Use of any medications from the following classes within 28 days prior to Visit 1: monoamine oxidase inhibitors, tricyclic antidepressants, beta blockers, non-potassium-sparing antihypertensive diuretics, or systemic corticosteroids
  • Baseline prolongation of QTc (QTc ≥ 460 ms by Fridericia's formula)
  • Self-reported pregnancy or lactating or breastfeeding
  • Body Mass Index (BMI) > 35 kg/m2 (class II or III obesity)
  • Self-reported combustible cigarette smoking of more than 1 pack per day
  • Greater than 20 pack-year smoking history

Where in United States

  • University of ColoradoAurora, United States
  • University of VermontBurlington, United States

About the trial

What the trial wants to find out

The overall aim in Part 1 is to compare the pharmacokinetic (PK)/pharmacodynamics (PD) relationship in intravenous (IV) versus subcutaneous (SQ) terbutaline sulfate to identify the optimal IV dosing range for use in Part 2.

Read full original descriptionShow less

The overall aim in Part 2 is to evaluate the optimal IV dosing of terbutaline sulfate based on PD response and safety data.

The 5 groups in the trial

  • Terbutaline Arm ATreatment being tested

    • Arm A: (n=6) IV bolus (0.25 mg) over 5 minutes SQ administration (0.25 mg) Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.

    Treatment: Terbutaline

  • Terbutaline Arm BTreatment being tested

    • Arm B: (n=6) SQ administration (0.25 mg) IV bolus (0.25 mg) over 5 minutes Participants in Part 1 Arms A and B (n=12) will be randomized to one of two treatment arms.No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.

    Treatment: Terbutaline

  • Terbutaline Arm CTreatment being tested

    • Arm C: (n=6) SQ (0.25 mg) IV low dose over 5 minutes IV medium dose over 5 minutes IV high dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.

    Treatment: Terbutaline

  • Terbutaline Arm DTreatment being tested

    • Arm D: (n=6)SQ (0.25 mg) IV medium dose over 5 minutes IV high dose over 5 minutes IV low dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.

    Treatment: Terbutaline

  • Terbutaline Arm ETreatment being tested

    • Arm E: (n=6) SQ (0.25 mg) IV high dose over 5 minutes IV low dose over 5 minutes IV medium dose over 5 minutes Participants in Part 2 (n=18) will be randomized to one of three treatment arms. To maintain masking the first treatment will be 0.25 mg of study drug SQ, followed by one of three IV dose regimes (low, medium, high) below, which are estimated to be 0.1 mg, 0.5 mg, 1.0 mg, but may be adjusted based on the interim analysis completed in Part 1. No masking will be applied for Part 1 or for the SQ dosing in Part 2. All IV treatments in Part 2 will be masked, with exception to the unmasked study pharmacist, refer to the MOP for details.

    Treatment: Terbutaline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma
Record updated
22 January 2026